View in EDS HTML Full Text PDF Full Text

Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.

Saved in:
Bibliographic Details
Title: Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Authors: Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain., Piasecka-Stryczynska K; Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland., Kuhle J; Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland., Benkert P; Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland., Arnold DL; Montreal Neurological Institute, McGill University, Montreal, QC, Canada; NeuroRx, Montreal, QC, Canada., Weber MS; Institute of Neuropathology, Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany; Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany., Seitzinger A; Merck Healthcare KGaA, Darmstadt, Germany., Guehring H; Merck Healthcare KGaA, Darmstadt, Germany., Shaw J; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Tomic D; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA., Hyvert Y; Merck Healthcare KGaA, Darmstadt, Germany., Harlow DE; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Dyroff M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Apr; Vol. 30 (4-5), pp. 558-570. Date of Electronic Publication: 2024 Mar 04.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38436271
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Montalban+X%22">Montalban X</searchLink>; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Piasecka-Stryczynska+K%22">Piasecka-Stryczynska K</searchLink>; Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.<br /><searchLink fieldCode="AU" term="%22Kuhle+J%22">Kuhle J</searchLink>; Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Benkert+P%22">Benkert P</searchLink>; Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Arnold+DL%22">Arnold DL</searchLink>; Montreal Neurological Institute, McGill University, Montreal, QC, Canada; NeuroRx, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Weber+MS%22">Weber MS</searchLink>; Institute of Neuropathology, Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany; Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany.<br /><searchLink fieldCode="AU" term="%22Seitzinger+A%22">Seitzinger A</searchLink>; Merck Healthcare KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Guehring+H%22">Guehring H</searchLink>; Merck Healthcare KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Shaw+J%22">Shaw J</searchLink>; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.<br /><searchLink fieldCode="AU" term="%22Tomic+D%22">Tomic D</searchLink>; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA.<br /><searchLink fieldCode="AU" term="%22Hyvert+Y%22">Hyvert Y</searchLink>; Merck Healthcare KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Harlow+DE%22">Harlow DE</searchLink>; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.<br /><searchLink fieldCode="AU" term="%22Dyroff+M%22">Dyroff M</searchLink>; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.<br /><searchLink fieldCode="AU" term="%22Wolinsky+JS%22">Wolinsky JS</searchLink>; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229509185%22">Multiple sclerosis (Houndmills, Basingstoke, England)</searchLink> [Mult Scler] 2024 Apr; Vol. 30 (4-5), pp. 558-570. <i>Date of Electronic Publication: </i>2024 Mar 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9509185 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-0970 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213524585%22">13524585 </searchLink><i>NLM ISO Abbreviation: </i>Mult Scler <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38436271
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/13524585241234783
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 558
    Titles:
      – TitleFull: Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Montalban X
      – PersonEntity:
          Name:
            NameFull: Piasecka-Stryczynska K
      – PersonEntity:
          Name:
            NameFull: Kuhle J
      – PersonEntity:
          Name:
            NameFull: Benkert P
      – PersonEntity:
          Name:
            NameFull: Arnold DL
      – PersonEntity:
          Name:
            NameFull: Weber MS
      – PersonEntity:
          Name:
            NameFull: Seitzinger A
      – PersonEntity:
          Name:
            NameFull: Guehring H
      – PersonEntity:
          Name:
            NameFull: Shaw J
      – PersonEntity:
          Name:
            NameFull: Tomic D
      – PersonEntity:
          Name:
            NameFull: Hyvert Y
      – PersonEntity:
          Name:
            NameFull: Harlow DE
      – PersonEntity:
          Name:
            NameFull: Dyroff M
      – PersonEntity:
          Name:
            NameFull: Wolinsky JS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1477-0970
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 4-5
          Titles:
            – TitleFull: Multiple sclerosis (Houndmills, Basingstoke, England)
              Type: main
ResultId 1